News

Press Release: PolyPeptide Group Selected by Novavax to Manufacture Critical Intermediates of Matrix-M™ Adjuvant for its COVID-19 Vaccine

The PolyPeptide Group, a global Contract Development and Manufacturing Organization (CDMO) for Peptide, Peptidomimetic and other Drug Substances, has announced that it has partnered with Novavax Inc. (NASDAQ: NVAX), a late-stage biotechnology company developing next-generation vaccines for serious infectious diseases, on large-scale GMP production of a critical component of Novavax’ novel coronavirus vaccine candidate, NVX-CoV2373. PolyPeptide Group will produce two key intermediates used in the production of Matrix-M™, the adjuvant component of the vaccine, which is being used to enhance the vaccine’s immune response and stimulate high levels of neutralizing antibodies. NVX-CoV2373 is a stable, prefusion protein made using Novavax’ proprietary nanoparticle technology.

Read the press release

PolyPeptide News Flash, #2, 2020

While the COVID-19 crisis continues, the PolyPeptide Group is actively engaged in helping find treatments and vaccines for COVID-19. See report on promising therapies in our latest Newsletter. We are also highlighting our ongoing Digitalization projects as well as introducing our new Global Director for Quality Control and Analytical Development, Eran Benjamin, read more

Information Letter on COVID-19

Download letter PDF here

 

Dear Valued Customer,

While the COVID-19 crisis continues, I want to assure you that the PolyPeptide Group remains ready to support your business. Our sites are operating at almost-full capacity. At the same time, we have put numerous steps in place to protect the health and safety of our employees, including rigorous cleaning and infection control procedures.

Our company is also actively engaged in helping to find treatments and cures for COVID-19. Within the next few weeks, we will have teams at almost all sites working on projects to:

1. Develop a peptide-based vaccine or vaccine cocktail against the virus


2. Use peptides as immuno-modulators to allow our own immune system to fight this disease


3. Use anti-inflammatory peptides to fight the excessive release of cytokines that this disease may cause


4. Develop entry-inhibiting peptides that may inhibit coronavirus’ ability to enter human lung cells

Jane Salik, CEO

Download letter PDF here

Information Letter on COVID-19

Download letter PDF here

 

New member of the Medicon Valley Alliance

We are happy to inform that the PolyPeptide Group is from now a member of the Medicon Valley Alliance (MVA). It is a non-profit membership organization, the leading life science cluster in Scandinavia and one of the largest in Europe. With this membership, we wish to strengthen our presence, support and knowledge sharing in the region as the global leader in Peptide Development and Manufacturing.

PolyPeptide News Flash February 2020

 

In 2019 we made significant progress in reducing solvent consumption. Our goal is to become the greenest solution provider for peptides, learn more in our February Newsletter.

 

Innovation and Technology

Innovation is considered as a key driver for the future of our business. In 2020 we will highlight our focus and progress on Innovation and Technology even more. Why is Innovation so important? Learn more in this new video. 

 

PolyPeptide News Flash October

Find out the latest news in our October Newsletter

 

Press release: the start of a research collaboration program with IBMM in Montpellier, France

PolyPeptide Group is pleased to announce the start of a research collaboration program with the Green Chemistry and Enabling Technologies Team of IBMM (Institut des Biomolécules Max Mousseron) in Montpellier. Read complete press release research_collaboration_program_IBMM_PolyPeptide

 

Symposium on Preparative and Process Scale HPLC, MCC and SFC 2019

PolyPeptide Group will be present at the Symposium on Preparative & Process Scale HPLC, MCC and SFC 2019 
on September 10-11 in Gothenburg, Sweden, to discuss the latest trends in preparative and process chromatography
among scientists and engineers from all over the world. Per Möller, Process Development, PolyPeptide Group, is one of
the speakers presenting “Strategies and Practical Considerations in the Downstream Process Development of Synthetic Peptides".
Read more​​

Book your meeting with PolyPeptide at CPhI worldwide - Frankfurt, Germany 5-7 November 2019

Meet PolyPeptide Group 5-7 November in Frankfurt, Germany. Contact your Sales Representative or send us an email: Generics.Sales@polypeptide.com to schedule a meeting.
We look forward to seeing you at booth 42F12.
Find out more about CPhI worldwide Europe

100% Sustainable energy from wind turbines at PolyPeptide Sweden

Polypeptide Laboratories (Sweden) AB reduces Carbon dioxide emissions with 2206 ton in 2019 when 100% of the electricity comes from wind power. PolyPeptide Group focuses on finding sustainable solutions, all ways, always.

See certification from E.ON (in swedish only)

PolyPeptide attends TIDES Europe - Amsterdam, November 7th and 8th

PolyPeptide attends TIDES Europe in Amsterdam, Postillion Convention Center, November 7th and 8th. Contact us: scandinavia@polypeptide.com to set a meeting or come by our booth #13.

Want to learn more about “Successful Characterization of Peptide APIs & Setting the Specifications Optimally”? Join the presentation Thursday, November 8th, 12:40 - 13:10 with Didier Monnaie, Head of Analytical Department, PolyPeptide Group. Read more here

Looking forward to seeing you at CPhI Madrid, 9-11 October, Hall 8, stand #8B2

Contact your PolyPeptide Sales Representative to schedule a meeting or send an email to: eu.generics.sales@polypeptide.com